TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Pulmonary Tuberculosis Clinical Trial

Official title:

TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00694629
• Other study ID #: CDC-NCHSTP-5399
• Status: Completed
• Phase: Phase 2
• First received: June 6, 2008
• Last updated: May 7, 2014
• Start date: December 2008
• Est. completion date: December 2013

Study information

• Verified date: May 2014
• Source: Centers for Disease Control and Prevention
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Protocol Synopsis The goal of this Phase 2 clinical trial is to evaluate the antimicrobial activity and safety of an experimental intensive phase (first 8 weeks of treatment) tuberculosis treatment regimen in which rifapentine is substituted for rifampin.

Primary Objective

• To compare the antimicrobial activity and safety of standard daily regimen comprised of rifampin (approximately 10 mg/kg/dose) + isoniazid + pyrazinamide + ethambutol (RHZE) to that of an experimental regimen comprised of rifapentine (approximately 10 mg/kg/dose) + isoniazid + pyrazinamide + ethambutol (PHZE).

Secondary Objectives

• To determine and compare for each regimen the time to culture-conversion, using data from 2-, 4-, 6-, and 8-week cultures (10, 20, 30, 40 doses).

• To determine and compare for each regimen the proportion of patients with any Grade 3 or 4 adverse reactions

• To determine the correlation of the MGIT/BACTEC liquid culture growth index and other mycobacterial and clinical biomarkers with time to culture conversion and treatment failure

• To store serum for future assessment of biomarkers of TB treatment response and hypersensitivity to study drugs.

• To compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients

• To determine the tolerability and safety, and estimate the antimicrobial activity, of experimental regimens that include isoniazid + pyrazinamide + ethambutol plus either rifapentine 15 mg/kg/dose or rifapentine 20 mg/kg/dose, all administered daily. Assessment of these doses of rifapentine will be performed as an extension to the main study after enrollment in the main study has been completed.

Design

This will be a prospective, multicenter, open-label clinical study. Adults suspected of having pulmonary tuberculosis who meet eligibility criteria will be randomized to receive either the experimental intensive phase tuberculosis treatment regimen or the standard intensive phase tuberculosis treatment regimen. Randomization will be stratified by presence/absence of cavitation on baseline chest radiograph, and by geographic continent. All doses of study drugs will be given under direct observation and administered 5 days per week. After a subject completes intensive phase therapy, he/she then will be treated with a non-experimental continuation phase tuberculosis treatment regimen.

The study extension will be a prospective, multicenter clinical trial. Eligibility criteria will be the same as for the main study. Participants will be randomized to one of four regimens: the standard intensive phase treatment regimen, an investigational regimen in which rifapentine 10 mg/kg/dose is substituted for rifampin, an investigational regimen in which rifapentine 15 mg/kg/dose is substituted for rifampin, or an investigational regimen in which rifapentine 20 mg/kg is substituted for rifampin. Randomization will be stratified by the presence/absence of cavitation on baseline chest radiograph, and by study site. Study drugs will be administered 7 days per week. After a subject completes intensive phase therapy, he/she then will be treated with a non-experimental continuation phase tuberculosis treatment regimen. Subjects will have blood drawn for one pharmacokinetic determination of rifapentine concentration at or after the week 2 visit during intensive phase therapy.

This study is being conducted in 2 phases.

1. The main study compares a 10 mg/kg dose of rifapentine, open label, against 10 mg/kg rifampin in an otherwise standard intensive phase regimen of treatment for pulmonary tuberculosis. The projected sample size was 480 enrollments; 530 patients were actually enrolled.

2. The study extension evaluates higher doses of rifapentine, with the specific rifapentine doses (10 mg/kg, 15 mg/kg, and 20 mg/kg) blinded to patients and clinicians, with data collection and endpoints otherwise similar to the main study. The projected sample size for the study extension is 320 enrollments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 865
• Est. completion date: December 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated or induced sputum.

2. Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 3 months prior to enrollment.

3. 5 (five) or fewer days of multidrug therapy for tuberculosis disease in the 6 months preceding initiation of study drugs.

4. 7 (seven) or fewer days of fluoroquinolone therapy in the 30 days preceding initiation of study drugs.

5. Age >= 18 years

6. Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs; see Appendix B)

7. Signed informed consent

8. Women of child-bearing potential must agree to practice an adequate (barrier) method of birth control or to abstain from heterosexual intercourse during study therapy.

9. Laboratory parameters done within 14 days prior to, enrollment:

• Serum or plasma alanine aminotransferase (ALT) activity = 3 times the upper limit of normal

• Serum or plasma total bilirubin level = 2.5 times the upper limit of normal

• Serum or plasma creatinine level = 2 times the upper limit of normal

• Complete blood count with hemoglobin level of at least 7.0 g/dL

• Complete blood count with platelet count of at least 100,000/mm3

• Negative pregnancy test (women of childbearing potential)

Exclusion Criteria:

1. Pregnant or breast-feeding

2. Known intolerance or allergy to any of the study drugs

3. Concomitant disorders or conditions for which isoniazid (INH), rifamycins, pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty arthritis.

4. Current or planned therapy, during the intensive phase of TB therapy, with combination antiretroviral therapy for HIV, or with cyclosporine or tacrolimus. Cyclosporine and tacrolimus have unacceptable interactions with rifamycins.

5. Pulmonary silicosis

6. Central nervous system TB

7. Weight < 40 kg or > 85 kg

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pulmonary Tuberculosis
• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Drug:
• rifampin
tablet, 10 mg/kg, daily, 8 weeks
• rifapentine
tablet, 10 mg/kg, daily, 8 weeks
• rifapentine
tablet, 15 mg/kg, daily, 8 weeks
• rifapentine
20 mg/kg, daily, 8 weeks

Locations

Country	Name	City	State
Brazil	Hopital Universitario Clementino Fraga Filho	Rio de Janeiro
Canada	Montreal Chest Institute McGill University	Montreal	Quebec
Canada	University of Manitoba	Winnepeg	Manitoba
South Africa	Nelson R Mandela School of Medicine	Durban	KwaZulu Natal
Spain	Agencia de Salut Publica	Barcelona
Uganda	Makerere University Medical School	Kampala
United States	Emory University School of Medicine	Atlanta	Georgia
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland
United States	Boston Medical Center	Boston	Massachusetts
United States	Chicago VA Medical Center (Lakeside)	Chicago	Illinois
United States	Northwestern University	Chicago	Illinois
United States	Denver Department of Public Health and Hospitals	Denver	Colorado
United States	Duke University Medical Center	Durham	North Carolina
United States	University of North Texas Health Science Center	Fort Worth	Texas
United States	Hines VA Medical Center	Hines	Illinois
United States	Houston Veterans Administration Medical Center	Houston	Texas
United States	Central Arkansas Veterans Health System	Little Rock	Arkansas
United States	LA County/USC Medical Center	Los Angeles	California
United States	University of Southern California Medical Center	Los Angeles	California
United States	Nashville VA Medical Center	Nashville	Tennessee
United States	Veterans Administration Tennessee Valley Health Care System	Nashville	Tennessee
United States	Columbia University/Presbyterian Medical Center	New York	New York
United States	Harlem Hospital, Columbia University	New York	New York
United States	New Jersey Medical School	Newark	New Jersey
United States	Audi L. Murphy VA Hospital	San Antonio	Texas
United States	University of California at San Diego	San Diego	California
United States	University of California, San Francincisco	San Francisco	California
United States	Seattle King County Health Department	Seattle	Washington
United States	Washington DC Veterans Administration Medical Center	Washington DC	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Centers for Disease Control and Prevention	Sanofi

Countries where clinical trial is conducted

United States,  Brazil,  Canada,  South Africa,  Spain,  Uganda, 

References & Publications (1)

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Substitution of rifapentine for rif — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients, by regimen, having negative sputum cultures at completion of eight weeks (40 doses) of treatment		completion of eight weeks (40 doses) of treatment	No
Primary	The proportion of patients, by regimen, who permanently discontinue the assigned study treatment for any reason during the first eight weeks		during the first eight weeks of treatment	Yes
Secondary	time to culture-conversion		2-, 4-, 6-, and 8-week cultures (10, 20, 30, 40 doses)	No
Secondary	proportion of patients with any Grade 3 or 4 adverse reactions		8 weeks	Yes
Secondary	correlation of the MGIT/BACTEC liquid culture growth index and other mycobacterial and clinical biomarkers with time to culture conversion and treatment failure		duration of TB treatment	No
Secondary	compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients		8 weeks	Yes
Secondary	• To determine the tolerability and safety, and estimate the antimicrobial activity, of experimental regimens that include higher doses of rifapentine.	• To determine the tolerability and safety, and estimate the antimicrobial activity, of experimental regimens that include isoniazid + pyrazinamide + ethambutol plus either rifapentine 15 mg/kg/dose or rifapentine 20 mg/kg/dose, all administered daily. Assessment of these doses of rifapentine will be performed as an extension to the main study after enrollment in the main study has been completed.	8 weeks.	Yes